Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Jennifer L. Huggins is active.

Publication


Featured researches published by Jennifer L. Huggins.


Arthritis Care and Research | 2007

Validation of the Pediatric Automated Neuropsychological Assessment Metrics in childhood-onset systemic lupus erythematosus.

Hermine I. Brunner; Marisa S. Klein-Gitelman; Frank Zelko; Erin C. Thomas; Jessica Hummel; Shannen Nelson; Jennifer L. Huggins; Megan L. Curran; Tresa Roebuck-Spencer; Dean W. Beebe; Jun Ying

To evaluate the reproducibility and validity of the Pediatric Automated Neuropsychological Assessment Metrics (Ped‐ANAM) when used in childhood‐onset systemic lupus erythematosus (cSLE).


The Journal of Rheumatology | 2012

Usefulness of Cellular Text Messaging for Improving Adherence Among Adolescents and Young Adults with Systemic Lupus Erythematosus

Tracy V. Ting; Deepa Kudalkar; Shannen Nelson; Sandra Cortina; Joshua Pendl; Shaaista Budhani; Jennifer Neville; Janalee Taylor; Jennifer L. Huggins; Dennis Drotar; Hermine I. Brunner

Objective. In a cohort of 70 patients with childhood-onset systemic lupus erythematosus (cSLE): to determine the baseline adherence to medications and visits; to investigate the effects of cellular text messaging reminders (CTMR) on adherence to clinic visits; and to study the influence of CTMR on adherence to use of hydroxychloroquine (HCQ). Methods. CTMR were sent to 70 patients prior to clinic visits for 14 months. A subgroup of patients were evaluated for medication adherence to HCQ: 19 patients receiving CTMR prior to each scheduled HCQ dose were compared to 22 patients randomized to standard of care education about HCQ. Visit adherence was measured using administrative databases. Pharmacy refill information, self-report of adherence, and HCQ blood levels were utilized to monitor medication adherence to HCQ. Sufficient adherence to visits or HCQ was defined as estimates > 80%. Disease activity was primarily monitored with the Systemic Lupus Erythematosus Disease Activity Index. Results. At baseline, 32% of patients were sufficiently adherent to HCQ, and 81% to clinic visits. Visit adherence improved significantly by > 80% among those who were nonadherent to clinic visits at the baseline CTMR (p = 0.01). CTMR did not influence adherence to HCQ over time. Conclusion. Patients with cSLE were only modestly adherent to HCQ and clinic visits. CTMR may be effective for improving visit adherence among adolescents and young adults with cSLE, but it does not improve adherence to HCQ.


Clinical Immunology | 2009

Macrophage activation syndrome: Serological markers and treatment with anti-thymocyte globulin

Andreea Coca; Kemp W. Bundy; Bethany Marston; Jennifer L. Huggins; R. John Looney

Two patients presented at the University of Rochester Medical Center with a febrile illness, cytopenias, organ failure (liver failure or respiratory failure), and markedly elevated serum ferritin and sIL-2R. A diagnosis of probable macrophage activation syndrome was made. Both patients failed initial therapy with steroids and cyclosporine, either due to toxicity or lack of efficacy. Both patients responded dramatically to rabbit anti-thymocyte globulin (ATG).


Arthritis Care and Research | 2013

International Consensus for Provisions of Quality‐Driven Care in Childhood‐Onset Systemic Lupus Erythematosus

Matthew C. Hollander; Jessica M. Sage; Alexandria J. Greenler; Joshua Pendl; Tadej Avcin; Graciela Espada; Michael W. Beresford; Michael Henrickson; Tsz Leung Lee; Marilynn Punaro; Jennifer L. Huggins; Anne M. Stevens; Marisa S. Klein-Gitelman; Hermine I. Brunner

To obtain international consensus around processes that support the delivery of high‐quality care to patients with childhood‐onset systemic lupus erythematosus (SLE) based on current recommendations and scientific evidence.


Arthritis Care and Research | 2016

Initial Benchmarking of the Quality of Medical Care in Childhood-Onset Systemic Lupus Erythematosus.

Rina Mina; Julia G. Harris; Marisa S. Klein-Gitelman; Simone Appenzeller; Maraisa Centeville; Diane Eskra; Jennifer L. Huggins; Anne Johnson; Raju Khubchandani; Prachi Khandekar; Jiha Lee; Hai Mei Liu; Joshua Pendl; Clovis A. Silva; Marco F. Silva; Ahmad Zaal; Esi Morgan DeWitt; Stacy P. Ardoin; Hermine I. Brunner

To assess the quality of medical care in childhood‐onset systemic lupus erythematosus (SLE) at tertiary pediatric rheumatology centers as measured by observance of SLE quality indicators (SLE‐QIs).


Pediatric Drugs | 2016

Adolescent Vaccination Strategies: Interventions to Increase Coverage.

Corinne Lehmann; Rebecca C. Brady; Reuben Oneal Battley; Jennifer L. Huggins

While vaccines have decreased the burden of disease, many adolescents still remain under-immunized, particularly for human papillomavirus (HPV) and influenza. We review the most current data regarding adolescent immunizations in the United States and discuss proven strategies that work for increasing vaccination rates. Strategies that have been shown to improve rates include provider feedback, immunization information systems (or registries), and enhanced access outside of provider offices, such as school-based immunization programs. Overall, practices may want to consider multimodal quality improvement approaches to enhance practice vaccination rates. The public health and cost benefits of immunizing adolescents are well known, yet recent measles outbreaks in the United States have highlighted issues with state immunization laws and vaccine refusals. Providers should be clear in their advice regarding vaccines and use effective reminder strategies as parents commonly cite not having enough information or knowledge that a vaccine was needed for their adolescent. Additional research is needed regarding adolescent consent for vaccines, as well as adolescent and parental refusal, in order to design systems that will help inform families and allow for widespread vaccine availability.


Arthritis & Rheumatism | 2014

A134: Validation of Patient Reported Outomes Measurement Information System Modules for use in Childhood‐;onset Lupus

Jordan T. Jones; Shannen L. Nelson; Janet Wootton; Jun Ying; Brianna Liberio; Alexandria J. Greenler; Kasha Wiley; Jiha Lee; Jennifer L. Huggins; Laura E. Schanberg; Brunner Hermine

Childhood‐onset lupus (cSLE) is a chronic autoimmune disease and its effect on health‐related quality of life (HRQoL) has not been systematically established. The Patient Reported Outcomes Measurement Information System (PROMIS™, http://nihpromis.org) is a publicly available system to measure patient reported outcomes that features electronic data collection. Although several validated legacy QoL measures exist for cSLE, each is longer than the PROMIS™ Pediatric Short Forms (Short Forms). The objective of this study was to investigate the feasibility, construct and discriminant validity of the Short Forms in cSLE in a clinical setting.


Lupus | 2016

Organ involvement other than lupus nephritis in childhood-onset systemic lupus erythematosus:

Jennifer L. Huggins; Michael J. Holland; Hermine I. Brunner

In this review we critically analyze pulmonary, gastrointestinal and cardiac manifestations of childhood-onset systemic lupus erythematosus (cSLE). Clinical manifestations of these organ systems may be the initial manifestation of cSLE; frequently occur with very active cSLE; and are potential life-threatening manifestations often presenting to the emergency department and requiring admission to the intensive care unit. Early recognition and treatment of the pulmonary, gastrointestinal and cardiac manifestations of cSLE will result in improved prognosis and better outcomes.


Arthritis & Rheumatism | 2018

Risk, Timing, and Predictors of Disease Flare After Discontinuation of Anti-Tumor Necrosis Factor Therapy in Children With Polyarticular Forms of Juvenile Idiopathic Arthritis With Clinically Inactive Disease

Daniel J. Lovell; Anne Johnson; Bin Huang; Beth S. Gottlieb; Paula W. Morris; Yukiko Kimura; Karen Onel; Suzanne C. Li; Alexei A. Grom; Janalee Taylor; Hermine I. Brunner; Jennifer L. Huggins; James J. Nocton; Kathleen A. Haines; Barbara Edelheit; Michael Shishov; Lawrence K. Jung; Calvin B. Williams; Melissa S Tesher; Denise M. Costanzo; Lawrence S. Zemel; Jason A. Dare; Murray H. Passo; Kaleo Ede; Judyann C. Olson; Elaine Cassidy; Thomas A. Griffin; Linda Wagner-Weiner; Jennifer E. Weiss; Larry B. Vogler

To determine the frequency, time to flare, and predictors of disease flare upon withdrawal of anti–tumor necrosis factor (anti‐TNF) therapy in children with polyarticular forms of juvenile idiopathic arthritis (JIA) who demonstrated ≥6 months of continuous clinically inactive disease.


Human Molecular Genetics | 2018

A plausibly causal functional lupus-associated risk variant in the STAT1–STAT4 locus

Zubin Patel; Xiaoming Lu; Daniel Miller; Carmy Forney; Joshua Lee; Arthur Lynch; Connor Schroeder; Lois Parks; Albert F. Magnusen; Xiaoting Chen; Mario Pujato; Avery Maddox; Erin E. Zoller; Bahram Namjou; Hermine I. Brunner; Michael Henrickson; Jennifer L. Huggins; Adrienne H. Williams; Julie T. Ziegler; Mary E. Comeau; Miranda C. Marion; Stuart B. Glenn; Adam Adler; Nan Shen; Swapan K. Nath; Anne M. Stevens; Barry I. Freedman; Bernardo A. Pons-Estel; Betty P. Tsao; Chaim O. Jacob

Systemic lupus erythematosus (SLE or lupus) (OMIM: 152700) is a chronic autoimmune disease with debilitating inflammation that affects multiple organ systems. The STAT1-STAT4 locus is one of the first and most highly replicated genetic loci associated with lupus risk. We performed a fine-mapping study to identify plausible causal variants within the STAT1-STAT4 locus associated with increased lupus disease risk. Using complementary frequentist and Bayesian approaches in trans-ancestral Discovery and Replication cohorts, we found one variant whose association with lupus risk is supported across ancestries in both the Discovery and Replication cohorts: rs11889341. In B cell lines from patients with lupus and healthy controls, the lupus risk allele of rs11889341 was associated with increased STAT1 expression. We demonstrated that the transcription factor HMGA1, a member of the HMG transcription factor family with an AT-hook DNA-binding domain, has enriched binding to the risk allele compared with the non-risk allele of rs11889341. We identified a genotype-dependent repressive element in the DNA within the intron of STAT4 surrounding rs11889341. Consistent with expression quantitative trait locus (eQTL) analysis, the lupus risk allele of rs11889341 decreased the activity of this putative repressor. Altogether, we present a plausible molecular mechanism for increased lupus risk at the STAT1-STAT4 locus in which the risk allele of rs11889341, the most probable causal variant, leads to elevated STAT1 expression in B cells due to decreased repressor activity mediated by increased binding of HMGA1.

Collaboration


Dive into the Jennifer L. Huggins's collaboration.

Top Co-Authors

Avatar

Hermine I. Brunner

Cincinnati Children's Hospital Medical Center

View shared research outputs
Top Co-Authors

Avatar

Joshua Pendl

Cincinnati Children's Hospital Medical Center

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Anne Johnson

Cincinnati Children's Hospital Medical Center

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Janalee Taylor

Cincinnati Children's Hospital Medical Center

View shared research outputs
Top Co-Authors

Avatar

Jiha Lee

University of Cincinnati

View shared research outputs
Top Co-Authors

Avatar

Jun Ying

University of Cincinnati Academic Health Center

View shared research outputs
Top Co-Authors

Avatar

Pamela Morgan

Cincinnati Children's Hospital Medical Center

View shared research outputs
Top Co-Authors

Avatar

Shannen Nelson

Cincinnati Children's Hospital Medical Center

View shared research outputs
Researchain Logo
Decentralizing Knowledge